Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2052W HIGH $1.55
Volume
16.06 M
Value Traded
142.90 K
Short % Float
11.65%
+15%Week
+337.68%1 Month
+85.19%3 Month
+26.61%6 Month
-83.45%5 Year
-99.48%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
100.01 M
EPS (TTM)
-0.46
P/E Ratio
-
Ent. Value
94.42 M
Total Shares
72.47 M
Float Shares
55.00 M
Insiders
1.73%
Institutions
37.31%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PDSB Catalyst Timeline
Dated clinical, regulatory and corporate events for PDS Biotechnology Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for PDS Biotechnology Corporation
482Total events
8Upcoming
117Tier-1 (high impact)
2015 to 2027Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPDS0301Presentation
PDS Biotech to host virtual KOL event on PDS0301 Phase 2 data in mCRC
advanced colorectal cancer with liver metastasessource ↗
▼Program DiscontinuationPDS0101FiledCorporate
Discontinuation of VERSATILE-003 Phase 3 trial and cessation of further internal investment in PDS0101
▲Pipeline PrioritizationPDS0301Corporate
Strategic refocus to prioritize PDS0301 as lead development program
◆Enrollment CompletePDS0101FiledTrial
Enrollment completion for VERSATILE-003
HPV16-positive recurrent/metastatic head and neck cancersource ↗
◆Interim AnalysisPDS0101FiledTrial
PFS data readout (interim analysis) for VERSATILE-003
HPV16-positive recurrent/metastatic head and neck cancersource ↗
◆Full ResultsPDS01ADCClinical Data
Preliminary data publication for PDS01ADC + docetaxel in metastatic castration resistant prostate cancer
Metastatic castration resistant prostate cancersource ↗
◆Protocol AmendmentPDS01ADCTrial
Adoption of amended protocol for PDS01ADC + docetaxel trial
Metastatic castration resistant prostate cancersource ↗
◆Full ResultsPDS0101FiledClinical Data
Phase 2 data publication for PDS0101 + CRT in cervical cancer
Cervical cancersource ↗
▲Protocol AmendmentPDS0101FiledTrial
Amended VERSATILE-003 protocol to incorporate PFS as interim primary endpoint
HPV16-positive recurrent and/or metastatic head and neck cancersource ↗
▲Oral PresentationPDS01ADCPresentation
Encouraging early results from NCI-led trial of PDS01ADC + docetaxel presented at AACR special conference on prostate cancer
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Patent GrantedPDS0101FiledIP / Competition
New patents granted in U.S. and Japan for PDS0101
▲Full ResultsPDS01ADCClinical Data
Publication of interim Phase 2 data from Stage 1 of NCI-led mCRC trial in JCO Oncology Advances
metastatic colorectal cancer (mCRC)source ↗
▲Full ResultsPDS01ADCClinical Data
Publication of positive clinical and immunological biomarker data from Stage 1 of NCI-led mCRC trial
metastatic colorectal cancersource ↗
▲PublicationPDS0301Presentation
Publication of positive clinical and immunological biomarker data from Stage 1 of NCI-led mCRC Phase 2 trial
metastatic colorectal cancersource ↗
▲Full ResultsPDS0301Clinical Data
Publication of positive clinical and immunological biomarker data from Stage 1 of NCI-led mCRC Phase 2 trial
metastatic colorectal cancersource ↗
▲Protocol AmendmentPDS0101FiledTrial
Adoption of amended protocol for Phase 3 VERSATILE-003 trial incorporating PFS as interim primary endpoint
HPV16-positive recurrent and/or metastatic head and neck cancersource ↗
▲Patent GrantedPDS0101FiledIP / Competition
Notice of Allowance for U.S. patent covering PDS0101
HPV16-positive head and neck cancerssource ↗
◆Protocol AmendmentPDS0101FiledTrial
Protocol amendment submitted to FDA for VERSATILE-003 to enable accelerated approval
HPV16-positive head and neck cancerssource ↗
▲Oral PresentationPDS01ADCPresentation
Preliminary results of PDS01ADC plus docetaxel in 3rd line mCRPC presented at AACR special conference
Metastatic Castration-Resistant Prostate Cancer (mCRPC)source ↗
◆Protocol AmendmentPDS0101FiledTrial
Submitted amended protocol for Phase 3 VERSATILE-003 trial changing PFS to primary endpoint
HPV16-positive recurrent and/or metastatic Head and Neck Cancersource ↗
▲Full ResultsPDS0101FiledClinical Data
Positive final results from VERSATILE-002 trial showing promising mOS and durable PFS
HPV16-positive recurrent and/or metastatic Head and Neck Cancersource ↗
◆FDA Feedback ReceivedPDS0101FiledFDA Meeting
FDA meeting minutes expected in January 2026
HPV16-positive recurrent and/or metastatic Head and Neck Cancersource ↗
▲Enrollment CompletePDS01ADCTrial
Completed enrollment in metastatic colorectal cancer trial
metastatic colorectal cancersource ↗
▲Patent GrantedPDS0101FiledIP / Competition
New patents granted in the U.S. and Japan for PDS0101
▲Oral PresentationPDS01ADCPresentation
Presented encouraging early results at AACR special conference on prostate cancer research
metastatic castration-resistant prostate cancersource ↗
●Protocol AmendmentPDS0101FiledTrial
Amended VERSATILE-003 Phase 3 trial protocol to incorporate PFS as interim primary endpoint
HPV16-positive recurrent and/or metastatic head and neck cancersource ↗
▲Enrollment UpdatePDS01ADCTrial
Advanced castration resistant prostate cancer trial continues to recruit well
advanced castration resistant prostate cancersource ↗
▼Enrollment PausedPDS0101FiledTrial
Enrollment paused pending restart after protocol amendment
HPV16-positive recurrent and/or metastatic head and neck cancersource ↗
◆Full ResultsPDS01ADCClinical Data
Final data readout for PDS01ADC + HAIP in colorectal cancer
Colorectal cancersource ↗
▲Patent GrantedPDS0101FiledIP / Competition
Japan Patent Office issued Patent No. 7783866 for PDS0101 with broad composition of matter and methods of use claims
▲Full ResultsPDS0101FiledClinical Data
Positive final results from VERSATILE-002 trial
HPV16-positive recurrent and/or metastatic Head and Neck Cancersource ↗
◆Type C MeetingPDS0101FiledFDA Meeting
Type C Meeting with FDA scheduled for December 2025 to discuss accelerated approval pathway for PDS0101
HPV16-positive recurrent and/or metastatic Head and Neck Cancersource ↗
▲Trial CompletionPDS0101FiledTrial
Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab
HPV16-Positive Recurrent/Metastatic Head and Neck Cancersource ↗
▼Equity OfferingCorporate
Sale of common stock and warrants for gross proceeds of approximately $5.3 million
▲Oral PresentationPDS0101FiledPresentation
Rapid oral abstract presentation at SITC 2025 on PDS0101 combination immunotherapy
HPV-associated malignanciessource ↗
▲Poster PresentationPDS01ADCPresentation
Poster presentation at SITC 2025 on PDS01ADC memory T cell expansion
advanced solid tumorssource ↗
◆Poster PresentationPDS01ADCPresentation
Poster presentation on increases in peripheral memory T cells with self-renewing properties in patients treated with tumor-targeting IL-12 immunocytokine therapy
advanced solid tumorssource ↗
◆Oral PresentationPDS0101FiledPresentation
Rapid oral abstract presentation on early changes in serum proteomic profiles predicting anti-tumor activity in patients with advanced HPV-associated malignancies treated with novel combination immunotherapy
advanced HPV-associated malignanciessource ↗
◆Poster PresentationPDS01ADCPresentation
Poster presentation on tumor-targeting IL-12 immunocytokine therapy increasing peripheral NK cells with phenotypes associated with increased tumor cell lysis
advanced solid tumorssource ↗
◆Type B MeetingPDS0101FiledFDA Meeting
FDA meeting request to discuss expedited approval pathway and protocol amendment
HPV16-positive Head and Neck Cancersource ↗
◆Protocol AmendmentPDS0101FiledTrial
Proposed amendment to VERSATILE-003 to add PFS as primary endpoint and reduce patient numbers
HPV16-positive Head and Neck Cancersource ↗
▼Trial PausedPDS0101FiledTrial
VERSATILE-003 trial temporarily paused pending FDA review of amendment
HPV16-positive Head and Neck Cancersource ↗
▲Full ResultsPDS0101FiledClinical Data
Final VERSATILE-002 data showing median PFS 6.3 months and median OS 39.3 months
HPV16-positive Head and Neck Cancersource ↗
◆Enrollment CompletePDS01ADCTrial
Anticipated completion of patient recruitment for colorectal cancer cohort
metastatic colorectal cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How PDSB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-11-07 | PDS0101 (Versamune® HPV) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F13 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 99%
Micro Cap(rank 653 of 660)
Percentile Rank
PDS Biotechnology Corporation has significant pipeline risk (13/100), with 1 assets in development, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab and PDS0101 Monoclonal antibodyCompletedNCT04260126 | Metastatic Head and Neck Cancer | Phase 2 | COMPLETED | 95 | May 14, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every PDSB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PDS01ADC | unresectable metastatic colorectal cancer | Phase 2 | 2026-04-15 | objective response rate: 78%; two year survival rate with PDS01ADC: >80%; two year survival rate without PDS01ADC: ~35%Read More | PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial 78% Objective Response Rate (ORR) with PDS01ADC; Parallel trialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Freitag Gregory GeneDirector | Buy | 15,060 15,060 held | $0.00 | 02/28/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in PDSB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 0 % | 417.00 K | 142.63 K |
PDSB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PDSB ranks across every disease it competes in
Competitive Position is a premium feature
See how PDSB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPDSB News
PDSB▼ -12.9%on this news
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
PDS Biotechnology Corporation announced a virtual key opinion leader event focused on PDS0301, an investigational treatment for advanced colorectal cancer with liver metastases. Dr. Jonathan M. Hernandez from the National Cancer Institute will discuss clinical outcomes from Phase 2 trials. The event aims to shed light on the efficacy of PDS0301 in patients with microsatellite stable colorectal liver metastases.
Read more →PDSB▲ +8.1%on this news
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
PDS Biotechnology announced the publication of Phase 2 trial results for PDS0101 combined with pembrolizumab in HPV16-positive recurrent/metastatic head and neck cancer. The trial showed a median overall survival of 39.3 months, significantly higher than standard treatments. The treatment was well-tolerated, with a low rate of severe adverse events. These findings support the potential of PDS0101 as a viable therapy for this patient population.
Read more →PDSB▲ +45.6%on this news· ran to +207% by day 3
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
PDS Biotechnology Corporation announced the initial closing of a $22.3 million PIPE financing, raising $11.3 million led by Nant Capital. The funds will support the development of PDS0301, an investigational treatment for metastatic colorectal cancer, which has shown promising trial results. Additionally, Dr. Patrick Soon-Shiong has been appointed to the board, enhancing the company's leadership.
Read more →PDSB▲ +36.4%on this news
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
PDS Biotech has secured up to $22.55 million in a PIPE financing led by Nant Capital, with Dr. Patrick Soon-Shiong joining its board. The funds will support the development of PDS0301, an immunocytokine showing promise in treating solid tumors, particularly in colorectal cancer. The financing includes an initial and contingent milestone closing, with significant participation from existing investors.
Read more →PDSBPDS Biotech Reports Second Quarter 2026 Financial Results
PDS Biotechnology Corporation reported its financial results for Q2 2026, highlighting a strategic refocus on PDS0301, its lead immunotherapy candidate. The company announced promising clinical trial results for PDS0301 in metastatic colorectal cancer, showing a 77.8% objective response rate and an 80% survival rate at 24 months. However, PDS0101's development will be deprioritized, leading to a net loss of $9.8 million for the quarter.
Read more →PDSB▼ -64.9%on this newsshared move
PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101
PDS Biotechnology Corporation has announced a strategic refocus on PDS0301, an immunocytokine targeting metastatic colorectal cancer, while seeking partnerships for PDS0101. Encouraging Phase 2 results show significant response rates in patients with metastatic colorectal cancer. The company aims to enhance the effectiveness of oncology therapies by remodeling the tumor microenvironment, addressing unmet medical needs in cancer treatment.
Read more →PDSB▲ +20.9%on this news
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
PDS Biotechnology Corporation reported its financial results for Q1 2026, highlighting significant clinical advancements. The company is focused on resuming enrollment in its amended Phase 3 trial for PDS0101, while also noting successful enrollment in trials for PDS01ADC. Financially, PDSB showed a reduced net loss compared to the previous year, reflecting improved operational efficiency.
Read more →PDSBPDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
PDS Biotechnology Corporation announced a conference call and webcast scheduled for May 13, 2026, to discuss its financial results for Q1 2026. The call will also include updates on clinical programs and corporate developments. The company is advancing its lead immunotherapy program, PDS0101, in pivotal trials for HPV16-positive head and neck cancers.
Read more →PDSBPrecision Designed Science for Cancer Patients NASDAQ: PDSB April 2026 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States S
PDS Biotechnology Corporation (PDSB) has released forward-looking statements regarding its development pipeline, including PDS0101, an innovative treatment targeting HPV-positive cancers. The company has reported successful disease control rates in recent clinical trials, especially for recurrent/metastatic head and neck squamous cell carcinoma. PDSB maintains collaborations with prominent cancer treatment institutions, emphasizing its strategic position in combating HPV-related cancers. However, the company also recognizes potential risks related to intellectual property, financing, and operational history as it navigates its future growth.
Read more →PDSB▲ +28.3%on this news
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
PDS Biotechnology Corporation announced positive interim Phase 2 clinical trial results for its immunocytokine, PDS01ADC, in treating unresectable metastatic colorectal cancer. The trial, published in the Journal of Clinical Oncology, demonstrated a 78% objective response rate and an over 80% two-year survival rate among participants. The therapy combines PDS01ADC with hepatic artery infusion pump therapy, targeting tumors directly while minimizing systemic exposure. These findings indicate promising potential for PDS01ADC in a patient population where traditional therapies have been largely ineffective.
Read more →PDSBPDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
PDS Biotechnology Corporation reported its financial results for 2025, highlighting progress in its clinical programs, particularly the VERSATILE-003 Phase 3 trial for PDS0101. The trial amendment aims to incorporate progression-free survival as an interim endpoint, potentially shortening its duration and reducing costs. Additionally, early results from the PDS01ADC trial showed promising outcomes in prostate cancer patients. The company also strengthened its intellectual property portfolio with new patents.
Read more →PDSB▲ +15.4%on this newsshared move
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
PDS Biotechnology Corporation has announced a conference call and webcast scheduled for March 30, 2026, to discuss its financial results for the fourth quarter and year ended December 31, 2025. The call will also include updates on clinical programs and corporate developments. The company is actively engaged in pivotal trials for its lead immunotherapy program targeting advanced HPV16-positive cancers.
Read more →PDSBPrecision Designed Science for Cancer Patients NASDAQ: PDSB February 2026 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United State
PDS Biotechnology Corporation announced forward-looking statements regarding its lead program, PDS0101 (Versamune HPV), aimed at treating HPV16-positive head and neck cancers. The company is preparing for a pivotal Phase 3 trial under the FDA's accelerated approval pathway, citing positive preliminary results. However, PDS Biotech faces challenges related to financing and uncertainties regarding the timing and outcomes of its clinical trials. Despite a promising innovative treatment platform, operational risks remain a significant concern for the future success of the company.
Read more →PDSBPDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
PDS Biotechnology Corporation has announced an amendment to its Phase 3 VERSATILE-003 trial protocol, incorporating progression-free survival (PFS) as an interim primary endpoint. This change aims to support a potential accelerated approval pathway for PDS0101 in treating HPV16-positive recurrent and/or metastatic head and neck cancer. The trial's primary endpoint for full approval remains median overall survival (mOS).
Read more →PDSBPDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
PDS Biotech announced preliminary results from a Phase 2 study of PDS01ADC in patients with metastatic castration-resistant prostate cancer, showing a median progression-free survival of 9.6 months. The study, led by the NCI, also reported a median PSA decline of 40%, indicating potential benefits of the treatment. These findings were presented at the AACR conference.
Read more →PDSBPDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
PDS Biotechnology Corporation announced the issuance of a Notice of Allowance for a new U.S. patent covering its lead asset, PDS0101. This patent enhances the company's intellectual property estate and, combined with anticipated biologics exclusivity, provides over 20 years of market protection. The company is advancing PDS0101 through the Phase 3 VERSATILE-003 clinical trial for HPV16-positive head and neck cancers.
Read more →PDSB▲ +7.7%on this news
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
PDS Biotech has submitted an amended protocol to the FDA for its Phase 3 VERSATILE-003 trial, changing the primary endpoint to Progression Free Survival (PFS). This change aims to facilitate an earlier evaluation and potentially accelerate the approval of PDS0101 for HPV16-positive cancers. The amendment follows positive results from the previous trial and retains median overall survival as a requirement for full approval.
Read more →About PDS Biotechnology Corporation
Headquarters303A COLLEGE ROAD EAST, PRINCETON, NJ, 08540
BIOPHARMAWATCH ELITE PLUS
Trade the next PDSB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime